Two stocks in Healthcare
GSK vs Haleon: profit, growth, debt and price compared
GSK is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Haleon is stronger on 3: profit margin, debt and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GSKGSK.L | HaleonHLN.L | |
|---|---|---|
| Net margin | 13.0% | Stronger: 14.6% |
| Revenue growth, past year | Stronger: +4.00% | +2.20% |
| Debt to equity | 129.6% | Stronger: 50.2% |
| Forward P/E | Stronger: 9.9× | 15.4× |
| Dividend yield | Stronger: 3.64% | 2.13% |
| Analysts | Hold · 21 | Stronger: Buy · 18 |
| From its 200-day average | Stronger: −0.8% | −3.3% |
Share price over the past year
- GSK+5.5%
- Haleon−7.1%
20 Nov 202518 Nov 2026
GSK or Haleon: which is stronger?
- HLN.L
Which is more profitable?
Haleon keeps more of each sale as profit: 14.6% against 13.0%.
- GSK.L
Which is growing its sales faster?
GSK is growing its sales faster: +4.00% over the past year, against +2.20%.
- HLN.L
Which has borrowed less?
Haleon has borrowed less: its debt is 50.2% of what its shareholders own, against 129.6% for GSK.
- GSK.L
Which costs less for the profit it is expected to make?
GSK costs less for the profit it is expected to make: 9.9× its forward earnings, against 15.4×.
- GSK.L
Which pays more in dividends?
GSK pays more back in dividends for what a share costs: 3.64% a year, against 2.13%.
- HLN.L
Which do analysts rate higher?
Analysts are warmer on Haleon: Buy, against Hold for GSK.
- GSK.L
Which is in the stronger price trend?
GSK's price is in the stronger trend: 0.8% below its 200-day average, against 3.3% below.
What each company does
GSK.LGSK
GSK plc, together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Reports results on 3 February 2027
HLN.LHaleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.